MGN1601: Updated Phase I/II data

Updated data from 10 evaluable patients who completed 12 weeks of treatment in the open-label, German Phase I/II ASET trial showed that MGN1601 led to median overall survival (OS) of >16 months and produced 7 cases of stable disease. The most common adverse events were mild fever, edema, exanthema, pruritus, intermittent arthralgia, fatigue and moderate soft tissue infection. Data were presented at the European Society for Medical Oncology meeting in Vienna. ...